

Index

A

Abyzov, A., 176
Acellular techniques stereolithography (SLA), 26
Acquired immunodeficiency syndrome (AIDS), 74
Acute myeloid leukemia (AML), 173
Additive biofabrication techniques, 27
Adeno-associated virus (AAV), 87, 88, 95
Adenovirus, 87–89
Adenovirus serotype, 5, 89
Adibi, H., 133–143
Adipose-derived mesenchymal stem cells (AMSCs), 29
Adipose tissue-derived stromal cells (ASCs)
 applications, 142
 cellular and molecular mechanisms, 140, 141
 definition, 139–140
 differentiation potential, 140
 factors, 140
 isolation and characterization, 140
 reference genes, 159–161
Aghayan, H., 133–143
Alavi-Moghadam, S., 119–128, 133–143
Alginate, 6
Allografts, 121
Altanerova, V., 109
Alzheimer's disease, 60–62
Amable, P.R., 160–162
Amano, S., 109
Antigen presenting cells (APC), 76
Antimicrobial peptides (AMPs), 135
Apte, U, 109
Arjmand, B., 119–128, 133–143
Arslan, Y.E., 21–35
ASCs, *see* Adipose tissue-derived stromal cells
Atasoy-Zeybek, A., 85–97
Autografts, 121
Autologous skin grafting, 122
Axonotmesis, 43
Ayanoğlu, F.B., 151–164

B

Bauer, G., 59
Bellei, B., 29
 β -cantenin, 138
Big Bang theory, 28

Bioactive ceramics, 8
Bioactive materials, 4
Biocompatibility, 4
Bioengineered scaffolds, 25
Bio-inert high strength ceramics, 8
Bio-inert materials, 4
Biomaterials
 ceramic-based biomaterials
 BCP scaffolds, 8, 10
 bio-ceramics, 8
 bone regeneration in rabbit models, 11, 12
 borate glass, 11
 fullerenes and nanodiamonds, 12
 graphene substrates, 12
 hydroxyapatite-based scaffolds, 11
 micro-CT and histological analysis, 11
 orthopaedic and dentistry applications, 8
 phosphate based glasses, 11
 porous melt-derived bioactive glass, 11
 silicate-based bioactive glass, 11
 composite material, 13
 current research, 13–14
 design requirements, 4–5
 history of origin, 3–4
 polymeric-based biomaterials
 advantages, 5
 chitosan-based well-aligned fibers, 6
 classification, 5
 hydrogel system, 9, 10
 natural polymers, 5–6
 physical and chemical properties, 5
 stepwise topographic strategy, 6, 7
 of tissues, 5
 Bioresorbable ceramics, 8
 Bio-tolerant materials, 4
 Biphasic calcium phosphate (BCP) scaffolds, 8, 10
 Bone marrow-derived mesenchymal stem cells
 (BM-MSCs), 106–107, 139, 140, 157–160
 Bone morphogenetic proteins (BMPs), 86
 Bone tissue engineering
 biomaterial-mediated non-viral gene delivery, 93–95
 biomaterial-mediated viral gene delivery, 95
 natural polymers, 93
 synthetic polymers, 93

- Borate glass, 11
 Bosch, P., 92
 Bozkurt, B.T., 73–80
 Bozo, I.Y., 95
 Brachial plexus avulsions, 44
 Brain-derived neurotrophic factor
 axonal sprouting, 47
 functional recovery, 47–48
 high affinity receptor, 45
 neuron survival, 46–47
 regeneration, 47
 remyelination, 47
 Brain-derived neurotrophic factor (BDNF), 46
 Breitbart, A.S., 92
 Budd, E., 1–14
 Bünger bands, 45
- C**
 Carbon-based materials, 11
 Carbon nanotubes (CNTs), 11, 12
 Cardiac stem cells (CSCs), 30, 162, 163
 Cell-assisted lipotransfer (CAL), 143
 Cell therapy, 35
 Cellulose, 6
 Chang, P.-C., 92, 94
 Chang, S.C.-N., 92, 94
 Chan, J.R., 47
 Chao, M.P., 172, 173
 Chen, J.-J., 106
 Chitin, 6
 Chitosan, 6
 Chromatolysis, 45
 Chronic myeloid leukemia (CML), 173
 Collagen, 6
 Coutu, D.L., 108, 109
 Crespo, M., 172, 175
 CRISPR/Cas9 technology, 170
 Cui, L., 107
 Curtin, C.M., 94
 Curtis, K.M., 158, 160
 Cytokines, 75
- D**
 Dai, K.R., 92
 Das, S.R., 56, 57
 de Campos, R.P., 163
 Decellularization process, 25–26, 31
 De la Rosa, M.B., 41–63
 Deniz-Hızlı, A.A., 73–80
 Dermagraft, 34
 Dezawa, M., 55–58
 Diabetic foot ulcer (DFU), 136
 Drago, J.L., 92
 Duan, H.-F., 109
- E**
 ECM, *see* Extracellular matrix
 Elçin, A.E., 151–164
 Elçin, Y.M., 151–164
 Electrospinning technique, 27–28
 Embryonic stem cells (ESCs), 28–30, 76
 Erten, E., 21–35
 Eskildsen, T., 108
 EV-associated RNAs therapy, 110
 Exosomes, 23–24, 32, 33, 106, 124
 MSC-derived
 biological properties, 125
 clinical applications, 125
 conventional methods, 124
 different phases, 125, 127
 extra-cellular vesicles, 124
 particular exosomal markers, 124
 therapeutic effects, 125–126
- Extracellular matrix (ECM), 79
 acellular, 24
 bioengineered scaffolds, 25
 composition/structure, 24
 decellularization process, 25–26
 electrospinning, 27–28
 phenotypic changes, 24
 three-dimensional printing, 26–27
 Extracellular vesicles (EV), 110
- F**
 Facilitated endogenous repair, 92
 Falahzadeh, K., 119–128, 133–143
 Familial adenomatous polyposis (FAP), 175
 Fanconi anemia, 111
 Fang, J., 93, 94
 Fang, S., 126
 Fibroblast growth factors (FGFs), 121
 Fink, T., 161
 Firestein, G.S., 109
 Folkman, J., 4
 Foreign body response (FBR), 3, 4
 Friedenstein, A.J., 104
 Funato, K., 174
 Fused deposition modeling (FDM), 26
- G**
 GAM-mediated gene therapy, 93–94
 Gao, F., 52, 109
 García-Olmo, D., 142
 Gastrointestinal tumors, 111
 Gazit, D., 91, 92
 Geiger, F., 94
 Gelatin, 6
 Gene-activated matrices (GAMs), 93
 Gene delivery strategies
 bone tissue engineering
 biomaterial-mediated non-viral gene delivery,
 93–95
 biomaterial-mediated viral gene delivery, 95
 natural polymers, 93
 synthetic polymers, 93
 clinical applications, 95–97
 ex vivo gene delivery, 87, 90–93
 in vivo gene delivery, 87, 89–91

- non-viral vectors, 89
- viral vector
 - AAV, 87, 88
 - adenovirus, 87–89
 - factors, 87
 - lentivirus, 87, 88
 - retrovirus, 87, 88
- Gene engineering of MSC (GEMSC), 106
- Gene therapy, 104
- Genetic modification, 106, 107
 - BM-MSC, 106–107
 - clinical trials, 110–112
 - exosomes, 106
 - extracellular vesicles, 110
 - gene engineering of MSC, 106
 - gene therapy, 106, 107
 - human placental decidua basalis MSCs, 110
 - human umbilical vein endothelial cells, 110
 - promotion of, 106, 108–109
 - and vectors, 106, 107
- Genome editing technologies, 170
- Gilany, K., 133–143
- Gingival stem cells (GSCs), 163
- Gingold, J.A., 169–178
- Glaucoma, 61
- Gliomas, 174
- Gluck, T., 3
- Gnecchi, M., 108
- Golchin, A., 103–113
- Gong, M., 110
- Goodarzi, P., 119–128, 133–143
- Granule, 137
- Granulocyte-macrophage colony stimulating factor (GM-CSF), 121
- Growth factor-based gene therapy, 96
- Gugala, Z., 91
- Gu, Y., 50
- H**
- Haider, H.K., 108
- Han, J., 109
- Harper, M.M., 61
- Hass, R., 108
- Hawking, S., 28
- Hematopoietic stem cells (HSCs), 162, 163
- Hereditary breast and ovarian cancer (HBOC) syndromes, 174–175
- Herschel, John F. W., 3
- Hodgkinson, C.P., 108
- Holmgren, G., 156
- Hou, H.-Y., 61
- Housekeeping genes, 153
- Hsu, W.K., 92
- Huang, F., 108
- Huang, J., 108
- Hu, L., 126
- Human adipose-derived mesenchymal stem cells (hAMSCs), 25
- Human fetal tissue-derived MSCs (hfMSCs), 161–162
- Human placental decidua basalis MSCs (hPDB-MSCs), 110
- Human umbilical vein endothelial cells (HUVECs), 110
- Huntington's disease, 60
- Hyaluronic acid (hyaluronan), 6
- Hyman, A.S., 3
- I**
- ICOVIR-5, 111
- Immune response, 24
- Immunomodulatory behavior
 - adaptive immune system, 75–76
 - aging status, 79
 - anoikis, 79
 - down-regulation, 76–77
 - implanted stem cells, 79
 - innate immune system, 74–75
 - safety concerns and challenges, 79–80
 - T cell dependent mechanism, 78
 - transfer of, 79
 - up-regulation, 77–78
 - wound healing, 78
- Induced pluripotent stem cells (iPSCs), 29, 30, 76, 106, 122
 - adenovirus, 170
 - advantages, 175–176
 - in cancer disease modeling, 172
 - acute myeloid leukemia, 173
 - chronic myeloid leukemia, 173
 - familial adenomatous polyposis, 175
 - gliomas, 174
 - hereditary breast and ovarian cancer syndromes, 174–175
 - Li-Fraumeni syndrome, 171
 - myelodysplastic syndrome, 173
 - Noonan syndrome, 173–174
 - pancreatic ductal adenocarcinoma, 174
 - challenges, 176–177
 - direct protein insertion, 170
 - episomal plasmids, 170
 - future research, 177
 - genome editing technologies, 170
 - minicircle vectors, 170
 - miRNA infection/transfection, 170
 - mRNA transfection, 170
 - reprogramming differentiated adult cells, 170
 - Sendai virus, 170
- Inducible nitric oxide synthase (iNOS), 77
- iPSCs, *see* Induced pluripotent stem cells
- Ischemic brain injury, 61
- Iser, I.C., 161
- Ishihara, A., 92
- Ishikawa, N., 58
- Ito, H., 94, 95
- J**
- Jacobi, A., 160
- Jones, L.L., 61
- Juvenile myelomonocytic leukemia (JMML), 173
- K**
- Keilhoff, G., 58
- Kelley, W.N., 109

- Kim, J., 174
 Kim, J.Y., 107
 Kite, C., 3
 Koefoed, M., 94
 Kolff, W., 3
 Kong, C.S.L., 169–178
 Kooreman, N.G., 177
 Kose, G.T., 85–97
 Kotini, A.G., 172, 173
 Kouyoumdjian, J.A., 43
 Kozik, E.M., 41–63
 Kırbaç, O.K., 73–80
 Kwak, H.S., 8
- L**
 Larijani, B., 119–128, 133–143
 Lee, D.-F., 169–178
 Lee, J., 109
 Lee, J.-S., 92–94
 Le Gallois, D., 3
 Lemma, S., 163
 Lentivirus, 87, 88
 Liang, X., 126
 Li, C., 108
 Lidwill, M.C., 3
 Lieberman, J.R., 91, 92
 Li-Fraumeni syndrome (LFS), 171
 Li, G.-C., 109
 Li, L.Y., 60
 Lim, S., 108
 Liu, Y., 108
 Liver Dialysis Unit™, 34
 Li, W., 32, 108
 Li, X., 126, 160, 162
 Lu, P., 61, 62
 Lv, F.-J., 108
- M**
 Macrophages, 74
 Maijenburg, M.W., 108
 Major histocompatibility complex class II (MHC II), 76
 Marey, E.-J., 3
 Matrix metalloproteinase (MMPs), 138, 139
 McKee, G.K., 3
 Melhem, M.R., 31
 Meng, F., 108
 Mesenchymal stem cells (MSCs), 29, 32, 42, 49
 cellular fusion, 52–53
 clinical applications, 104–105
 clinical trials, 53–54
 genetic modification, 106, 107
 Alzheimer's disease, 60–61
 BM-MSc, 106–107
 clinical trials, 110–112
 exosomes, 106
 extracellular vesicles, 110
 gene engineering of MSC, 106
 gene therapy, 106, 107
 glaucoma, 61
 human placental decidua basalis MSCs, 110
 human umbilical vein endothelial cells, 110
 Huntington's disease, 60
 ischemic brain injury, 61
 Parkinson's Disease, 60
 peripheral nerve injury, 62
 promotion of, 106, 108–109
 spinal cord injuries, 61–62
 and vectors, 106, 107
 immunomodulatory behavior
 adaptive immune system, 75–76
 aging status, 79
 anoikis, 79
 down-regulation, 76–77
 implanted stem cells, 79
 innate immune system, 74–75
 safety concerns and challenges, 79–80
 T cell dependent mechanism, 78
 transfer of, 79
 up-regulation, 77–78
 wound healing, 78
 immuno-modulatory effects, 52
 limitations and barriers, 105
 multipotent MSCs, 49, 50, 104
 neurotrophins secretion, 49–52
 tMSCs, 54–59
 beneficial properties of, 57–59
 co-cultures, 54–55
 electrical transdifferentiation, 56–57
 genetic modification, 56
 small molecules, 55–56
 transplantation, 54
 MicroRNAs (miRNA), 106
 Millesi, H., 44
 Mimura, T., 58
 Mobasher, A., 1–14
 Mohamadi-Jahani, F., 119–128
 Molecular patterns, 74
 Moloney murine leukemia virus (MoMLV), 88
 Mononuclear leukocytes, 137
 Moriyama, H., 108
 Mousavi, M., 119–128
 Mozafari, M., 1–14
 MSC-derived exosomes (MSC-EXO)
 biological properties, 125
 clinical applications, 125
 conventional methods, 124
 different phases, 125, 127
 extra-cellular vesicles, 124
 particular exosomal markers, 124
 therapeutic effects, 125–126
 MSCs, *see* Mesenchymal stem cells
 Mulero-Navarro, S., 172–174
 Multi-walled carbon nanotubes (MWCNTs), 12
 Munoz, J.L., 108
 Myelodysplastic syndrome (MDS), 173
- N**
 Nakamura, Y., 108
 Nanodiamonds (NDs), 12
 Natural killer (NK) cells., 75
 Natural wound healing process, 120
 Nerve transfer method, 44

Neural progenitor cells (NPCs), 30, 31
 Neural stem cell (NCS), 30, 32
 Neurapraxia, 43
 Neuroblastoma (NB), 111
 Neurogenesis, 43
 Neutrophils, 74
 Niess, H., 109
 Nitric oxide (NO), 77
 Nommeots-Nomm, A., 11
 Non-embryonic stem cells, 28
 Non-viral vectors, 89, 106, 107
 Noonan syndrome (NS), 173–174
 No-tissue formation, 22
 Nourani, M.R., 103–113
 Nowakowski, A., 108

O

Optimum scaffold pore size, 4
 Osteogenesis imperfecta, 96
 Osteoporosis, 95

P

Palombella, S., 161
 Pancreatic ductal adenocarcinoma (PDAC), 174
 Parkinson's disease, 60
 Payab, M., 119–128, 133–143
 Pennisi, C.P., 1–14
 Peripheral nerve injuries (PNIs)
 brain-derived neurotrophic factor
 axonal sprouting, 47
 functional recovery, 47–48
 high affinity receptor, 45
 neuron survival, 46–47
 regeneration, 47
 remyelination, 47
 causes and prevalence, 43–44
 current treatment options, 44–45
 mechanisms, 43–44
 mesenchymal stem cells
 cellular fusion, 52–53
 clinical trials, 53–54
 genetically modified, 59–62
 immuno-modulatory effects, 52
 multipotent bone, 49, 50
 neurotrophins secretion, 49–52
 transdifferentiation, 54–59
 Schwann cells, 48–49
 Wallerian degeneration, 45–46
 Peripheral nerve injury, 62
 Peterson, B., 92
 Phosphate based glasses, 11
 Pirmoradi, S., 108
 Platelet-derived growth factors (PDGFs), 121, 122
 PNIs, *see* Peripheral nerve injuries
 Pollock, K., 60
 Polymorphonuclear leukocytes (PMNs), 137
 Porous melt-derived bioactive glass, 11
 Postparalytic syndromes, 44
 Powder-fusion printing (PFP), 26

Pressure ulcer, 136
 Primary platelet plug, 137
 Pulmonary fibrosis, 112

Q

Quantitative real-time polymerase chain reaction (qRT-PCR)
 accuracy result, 152
 to identify gene expression, 152
 stem cell
 normalization methods, 153–154
 pluripotent stem cell studies, 154–156
 user-friendly technique, 152
 Quantum dots (QDs), 11
 Quiroz, F.G., 157, 160

R

Raaijmakers, M.H., 162, 163
 Rabbit calvarial defect model, 8, 10
 Ragni, E., 160–162
 Rahim, F., 133–143
 Rahmati, M., 1–14
 Ranjbaran, N., 119–128
 RANKL, 96
 Rauh, J., 158, 160
 Recombinant human BMP-2, 96
 Reference genes
 cancer stem cells, 162, 163
 gingival stem cells, 163
 hematopoietic stem cells, 162, 163
 mesenchymal stem cell studies
 adipose stem cells, 159–161
 bone marrow-derived mesenchymal stem cells, 157–160
 human fetal tissue-derived MSCs, 161–162
 stem cell qRT-PCR Studies
 normalization methods, 153–154
 pluripotent stem cell studies, 154–156
 Regenerative medicine (RM), 104
 Rekabgardan, M., 103–113
 Ren, Z., 60
 Retrovirus, 87, 88
 Ridley, H., 3
 Rigotti, G., 142
 Ripa, R.S., 110
 Rodbell, M., 140
 Rosenzweig, E.S., 30
 Rubina Baglio, S.R., 110

S

Sage, E.K., 109
 Şahin, F., 73–80
 Sakaguchi, D.S., 41–63
 Sancho-Martinez, I., 172, 174
 Sarvari, M., 133–143
 Sasaki, M., 61
 Scaffold-based therapy, 27
 Schildberg, T., 160
 Schmittgen, T.D., 153

- Schwann cells (SCs), 42, 48–49
 Serwold, T., 177
 Shabbir, A., 126
 Sharma, A.D., 59
 Shen, H.-C., 92
 Shimizu, S., 58
 Shin, J.-H., 92
 Signaling molecules, 22–23
 Silicate-based bioactive glass, 11
 Single-walled carbon nanotubes (SWCNTs), 12
 Small interfering RNA (siRNA), 110
 Soyombo, A.A., 172, 174, 175
 Spinal cord injuries, 61–62
 Stem cells
 adipose-derived mesenchymal stem cells, 29
 Big Bang theory, 28
 biomaterials, 30–32
 cardiac stem cells, 30
 embryonic stem cells, 28–30
 induced pluripotent stem cells, 29, 30
 mesenchymal stem cells, 29
 neural progenitor cells, 30
 neural stem cells, 30
 non-embryonic stem cells, 28
 self-renewal process, 28
 stem cell-derived exosome/scaffold constructs, 32, 33
 symmetrical/asymmetrical, 28
 Stem cell therapy, 122
 Studer, D., 158, 160
 Suknutha, K., 172, 173
 Sun, Z., 109
 Su, X., 161
 Synnergren, J., 156
- T**
 Taheri, R.A., 103–113
 Taihi, I., 163
 Takahashi, K., 29, 170
 Tanaka, M., 12
 Tantrawatpan, C., 108
 Taşlı, P.N., 73–80
 Tayanloo-Beik, A., 119–128, 133–143
 T-helper cells, 76
 Thoma, E.C., 63
 Three-dimensional printing, 26–27
 Tissue engineering, 22, 23, 32–35
 Tissue inhibitors of metalloproteinases (TIMPs), 138, 139
 tMSCs, *see* Transdifferentiation mesenchymal stem cells
 Toll-like receptors (TLR), 75
 Transcription activator-like effector nuclease (TALEN)
 platforms, 171
 TransCyte, 34
 Transdifferentiation mesenchymal stem cells (tMSCs),
 54–59
 beneficial properties of, 57–59
 co-cultures, 54–55
 electrical transdifferentiation, 56–57
 genetic modification, 56
 small molecules, 55–56
 transplantation, 54
 Transforming growth factor β (TGF- β), 138
- Tratwal, J., 160, 161
 Tsubokawa, T., 108
 Turgeman, G., 96
 Tuszyński, M.H., 61
- V**
 Vandesompele, J., 158
 Vascular permeability factor (VPF), 137
 Venous leg ulcers (VLU), 136
 Vierbuchen, T., 56
 Viggewarapu, M., 92
 Viral vector, 106, 107
 AAV, 87, 88
 adenovirus, 87–89
 factors, 87
 lentivirus, 87, 88
 retrovirus, 87, 88
 Virk, M.S., 91, 92
 Vizzardo, R., 177
 Vossaert, L., 155, 156
- W**
 Wakao, S., 58
 Walesky, C., 109
 Wallerian degeneration, 45–46
 Wang, J.C., 96
 Wang, M., 109
 Watson-Farrar, J., 3
 Weintraub, H., 56
 Whole tissue/organ decellularization, 24
 Willems, E., 155, 156
 Won, Y.-W., 108
 Wound, 120
 chronic, 136
 closure, 136
 full thickness wounds, 136
 partial-thickness or deep dermal wounds, 136
 superficial wounds, 136
 see also Wound healing
 see also Wound regeneration
 Wound closure, 136
 Wound healing
 adipose tissue-derived stromal cells
 applications, 142
 cellular and molecular mechanisms, 140, 141
 definition, 139–140
 differentiation potential, 140
 factors, 140
 isolation and characterization, 140
 advantages, 135
 definition, 136
 inflammation, 137
 proliferation, 137–138
 remodeling, 138–139
 skin, 135
 Wound regeneration
 growth factors and cytokines, 121–122
 mesenchymal stem cells, 123
 MSC-derived exosomes
 biological properties, 125
 clinical applications, 125

- conventional methods, 124
 - extra-cellular vesicles, 124
 - particular exosomal markers, 124
 - therapeutic effects, 125–126
 - skin substitutes, 121
 - stem cells, 122
 - tissue engineering, 122
 - wound dressings, 121
- Wu, N., 109
- Wurster, D., 3
- Wurster process, 4
- X**
- Xenografts, 121
- Xie, C., 109
- Xin, H., 110
- X-linked severe combined immunodeficiency disease (SCID), 87
- Xue, C., 54
- Xu, G., 109
- Xu, X.L., 92
- Xyloglucan, 6
- Y**
- Yamanaka, S., 29, 170
- Yan, J., 106
- Yeh, T.-S., 109
- Young, M.A., 176
- Youssef, A., 108
- Yuan, Z., 108
- Z**
- Zakrajsek, B.A., 153
- Zhang, B., 126
- Zhang, C., 6
- Zhang, J., 126
- Zhang, J.Y., 47
- Zhang, Q.-Z., 109
- Zhang, Y., 94, 95
- Zhao, R., 169–178
- Zhou, S.H., 106
- Zhu, D., 169–178
- Zinc finger nuclease (ZFN), 171
- Zomer, H.D., 108